cancer therapy ͉ P-glycoprotein
H
ypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the synthesis and release of GH in the pituitary gland. GHRH and its mRNA are also expressed in many human cancers and cancer cell lines and in some normal tissues, suggesting that GHRH may act as a tumor growth factor (1, 2) . Although pituitary-type GHRH receptors cannot be detected in most human tumors by RT-PCR or radioligandbinding assays, the expression of tumor-specific splice variants of this receptor has been demonstrated (2) (3) (4) (5) (6) . Numerous studies show that antagonistic analogs of GHRH have inhibitory effects on the growth of various human cancer cell lines xenografted into nude mice, including osteosarcomas (7), glioblastomas (8) , small cell lung carcinomas (SCLC), non-SCLC (9) , and ovarian (10) , breast (11) , colorectal (12) , pancreatic (13) , prostatic (14) , and renal (5, 15) cancers.
Splice variants of tumoral GHRH receptors have been identified in various human cancer cell lines, including prostatic, pancreatic, breast and ovarian, colorectal, gastric, small cell lung carcinomas, and osteosarcomas, and also were detected in primary specimens of human prostate cancer (1, 3-7, 10, 14, 16) . Radioligand-binding studies using a 125 I-labeled GHRH antagonistic analog, JV-1-42, confirmed that specific high-affinity binding sites for GHRH and its synthetic antagonists were present in membrane fractions of 60% of the primary prostate tumors examined (4) . In vivo, these antagonists have both direct and indirect effects on the secretion of insulin-like growth factor I (IGF-I) and -II (1, 2) . GHRH antagonists can indirectly lower the levels of IGF-I in the serum by blocking the release of GH from the pituitary, an effect that reduces IGF-I synthesis in the liver and other tissues. These antagonists also have direct effects on GHRH receptors on tumors, an effect that may be associated with a reduction in IGF-I and -II in tumor tissue. Glioblastomas are the most frequent primary brain tumor subtype in adults. The dominant therapeutic approach to treat these tumors is surgical removal. Because malignant gliomas are characterized by aggressive proliferation and expansion into surrounding brain tissue, it is difficult to completely remove the tumor (17) . GHRH antagonists (MZ-5-156 and JV-1-36) have been shown to reduce the tumorigenicity and growth of U-87MG human glioblastomas transplanted onto mouse flanks (8) . However, the clinical use of these analogs will remain limited unless it is shown that they can cross the blood-brain barrier in quantities sufficient to elicit a tumoricidal response within the CNS. The brain capillary endothelial cells are joined together by tight junctions to form the blood-brain barrier. These tight junctions prevent significant paracellular diffusion of small molecules between blood and brain. Instead, entry of most molecules into the brain is mediated by membrane diffusion or specialized transport systems. Specific transport proteins exist for the movement of small hydrophilic molecules such as glucose, amino acids (18) , thyroid hormone (19) , and nucleosides (20) across the blood-brain barrier. Larger molecules such as leptin (21) and some cytokines (22) are also transported across the brain capillary endothelial cells by saturable processes. Membrane diffusion across the blood-brain barrier is directly correlated with the lipid solubility of a molecule.
In the present study, we tested the ability of a radioactively labeled GHRH antagonist (JV-1-42) to cross the blood-brain barrier. We found that peripherally administered iodinated JV-1-42 rapidly crosses the blood-brain barrier in therapeutically relevant quantities, indicating this compound holds great potential for the treatment of malignant gliomas.
Methods
Radioiodination of GHRH Antagonist JV-1-42. The GHRH antagonist JV-1-42 was radioactively labeled with 131 I using a modified version of the chloramine-T method that was described previously (4). First, 10 g of JV-1-42 was dissolved in 10 l of 0.01 M aqueous acetic acid. This was then added to 80 l of 0.1 M NH 4 OAc in 50% (vol͞vol) aqueous acetonitrile (pH ϭ 6.5-7). Next, 10 g of chloramine-T [dissolved in a solution of 0.1 M NH 4 OAc in 50% (vol͞vol) aqueous acetonitrile] was added. Approximately 2 mCi (1 Ci ϭ 37 GBq) of 131 I (PerkinElmer) was added to the mix and, after 45 sec at room temperature, the reaction was stopped by adding 50 g of L-cysteine dissolved in 10 l 0.01 M HCl. Radioactively labeled JV-1-42 ( 131 I-JV-1-42) was separated from free 131 I by reverse-phase HPLC (Shimadzu) on a Vydac 214TP54 column (P. J. Cobert and Associates, St. Louis). The radioactively labeled JV-1-42 was eluted with a linear gradient of 45-65% solvent B [0.1% aqueous trifluoroacetic acid in 70% (vol͞vol) aqueous acetonitrile] over a period of 50 min against solvent A [0.1% (vol͞vol) aqueous trifluoroacetic acid in HPLC grade water]. Fractions were collected in polypropylene tubes that were siliconized by using Sigmacote (Sigma), because the radioiodinated derivative adsorbs strongly to the surface of borosilicate glass and polypropylene tubes. Fifty 1-ml fractions were collected and the radioactivity measured by counting 1-l fractions in a gamma counter. The four fractions corresponding to the monoiodinated compound were identified by elution position as well as a peak in radioactivity. Fractions were dried for 1 h and then stored at Ϫ70°C.
Radioactive Labeling of Albumin with 99m Tc. The reaction mixture consisted of 0.12 mg of stannous tartrate, 1 mg of BSA, and 500 l of distilled water. The pH of this mixture was adjusted to 2.2-3.3 with 0.2 M HCl. Approximately 1 mCi of 99m Tc in NaOH was added to the mixture along with 500 l of distilled water. The mixture was allowed to incubate at room temperature for 20 min before total radioactivity was measured in a gamma counter.
Determination of Octanol͞Buffer Partition Coefficient. Lipid solubility of 131 I-JV-1-42 was determined by adding 1 ϫ 10 5 cpm of 131 I-JV-1-42 to 0.5 ml of 0.25 M chloride-free sodium phosphate buffer (pH ϭ 7.5) and 0.5 ml of octanol. This solution was vigorously mixed for 1 min. The two phases were separated by centrifugation at 5,000 ϫ g for 10 min. Aliquots of 100 l were taken in triplicate from each phase, and total radioactivity was measured for each aliquot in a gamma counter. The partition coefficient was calculated from the following formula:
Octanol͞buffer partition coefficient ϭ (octanol phase cpm)͞ (phosphate buffer phase cpm). Male CD-1 mice (Charles River Breeding Laboratories) weighing 20-25 g were anesthetized with 0.2 ml of i.p. urethane. Next, the skin from the neck was removed to expose the jugular vein and carotid artery. Each mouse was given an injection into the jugular vein of 0.2 ml of lactated Ringer's solution (LR) (Baxter Health Care, Deerfield, IL) containing 1% BSA (LR-BSA) and 3 ϫ 10 5 cpm of 131 I-JV-1-42. Blood was collected from the carotid artery 2-120 min after i.v. injection, the mouse was decapitated, and the brain removed and weighed. The whole arterial blood was centrifuged at 5,000 ϫ g for 10 min and the level of radioactivity determined in the serum and brain. To determine rate of clearance of 131 I-JV-1-42 from the serum after i.v. injection, the log of the injected dose in each milliliter of serum (log %Inj͞ml) was plotted against time (min).
Determination of Blood-to-Brain Influx Rate. The rate of uptake of 131 I-JV-1-42 from the blood to the brain was determined by using multiple time regression analysis (23, 24) . For the purpose of this analysis, a graph was created in which the brain͞serum ratios for time points ranging from 2 to 60 min after i.v. injection were plotted against their respective exposure times (Expt). The slope of the linear portion of this relation represents the unidirectional influx rate (K i ), and the y intercept represents the initial volume of distribution (V i ). Experimental clock time was reexpressed as exposure time (Expt) to correct for clearance of 131 I-JV-1-42 from the serum. Expt was calculated from the following formula:
where t is time, C p represents the level of radioactivity in the serum, and C p t is the level of radioactivity in the serum at time t. Without this correction, K i would be overestimated.
The percent of the injected dose taken up by each gram of brain tissue (%Inj͞g) was calculated from the following formula: To determine whether brain uptake of 131 I-JV-1-42 was a saturable process, 1 g per mouse of unlabeled JV-1-42 was included in the i.v. injection. Brain and serum samples were collected 10 min after i.v. injection, and results were expressed as brain͞serum ratios.
Determination of Brain-to-Blood Efflux Rate. The method has been used previously to quantify the rate of transport from brain to blood (25) . First, mice were anesthetized with an i.p. injection of 0.2 ml of urethane. After removal of the scalp, a hole through the cranium (1.0 mm lateral and 0.5 mm posterior to bregma) was created with a 26-gauge needle. The needle was covered with polyethylene-10 (PE-10) tubing, with the final 2.5-3.0 mm of the tip exposed. This ensured that the needle did not penetrate the floor of the ventricle. One microliter of LR-BSA containing 5 ϫ 10 3 cpm of 131 I-JV-1-42 was then injected into the lateral ventricle of the brain with a 1.0-l Hamilton syringe.
Mice were decapitated at 2, 5, 10, and 20 min after injection, the brain was removed, and the amount of radioactivity was measured by a gamma counter. The amount of radioactivity in the brain at t ϭ 0 was estimated in mice overdosed with urethane. These mice were killed and 15 min later injected with 131 I-JV-1-42. Brains were removed from these mice 10 min after injection. The log of the mean level of radioactivity in each brain was plotted against time (in minutes). Two sets of three mice were used at each of the five time points, and the mean of the three mice in each set was used. Eff lux curves were calculated with n ϭ 10 based on triplicates.
To determine whether efflux of 131 I-JV-1-42 was saturable, 100 ng of unlabeled JV-1-42 per mouse was included in the injection. To determine the role of P-glycoprotein (P-gp), 100 ng of cyclosporin A per mouse or 5 nM verapamil per mouse was included in the injection per mouse to test for ability to inhibit influx. Brain samples were collected 10 min after injection, and results are expressed as the mean percent of the intracerebroventricular (i.c.v.) injected dose taken up per gram of brain (%Inj͞Brain).
Capillary Depletion With and Without Vascular Washout. The capillary depletion method (26) as modified for mice (27) was performed to separate the cerebral capillaries from the parenchymal tissue so the compartmental distribution of 131 I-JV-1-42 could be determined. Male CD-1 mice were anesthetized by i.p. injection of 0.2 ml of urethane. Each mouse received an injection of 3 ϫ 10 5 cpm of 131 I-JV-1-42 and 3 ϫ 10 5 cpm 99m Tc-albumin in 0.8 ml of LR-BSA into the jugular vein. Mice were then divided into two groups (washout or no washout). Next, the abdomen was opened, and arterial blood was collected from the abdominal aorta at either 10, 30, or 60 min after i.v. injection. For the washout group, the descending thoracic aorta was clamped to cut off the circulation to the lower extremities. Both jugular veins were then severed, and a 20-ml syringe with an 18-gauge needle was inserted into the left ventricle of the heart. The 20 ml of lactated Ringer's solution (LR) was infused into the mouse over a period of 1-2 min. This infusion circulates through the brain microvessels, washes out the vascular space of the brain, and drains from the severed jugular veins.
After perfusion (washout group) or collection of arterial blood (no washout group), the brain was removed, weighed, and placed in a glass homogenizer containing 0.8 ml of physiologic buffer (10 mM Hepes͞141 mM NaCl͞4 mM KCl͞2.8 mM CaCl 2 ͞1 mM MgSO 4 ͞1 mM NaH 2 PO 4 ͞10 mM D-glucose; this buffer was then adjusted to pH ϭ 7.4). After 10 strokes with the glass pestle in the homogenizer, 1.6 ml of the physiologic buffer containing 26% dextran was added to the homogenate, vortexed, and then homogenized a second time (three strokes). All homogenization steps were performed on ice. The homogenate was centrifuged at 5,400 ϫ g for 15 min at 4°C in a Beckman Allegra-21R centrifuge with a swinging bucket rotor. The supernatant containing the brain parenchyma was separated from the pellet containing the brain microvasculature, and the level of To collect CSF, skin from the top of the head was removed to expose the skull, and a 30-gauge needle connected to a 25-cm length of PE-10 tubing was inserted Ϸ5 mm into the base of the skull at the level of the posterior fossa. Once the needle was inserted, CSF from the posterior fossa flowed into the PE-10 tubing by capillary action. After obtaining the CSF, the needle was removed and arterial blood collected from the carotid artery. Finally, the mouse was decapitated and the whole brain removed. The total amount of CSF collected was determined (in microliters) by measuring the length of PE-10 tubing filled with CSF (in centimeters) and multiplying this value by 0.668 (the volume in microliters present in 1 cm of PE-10 tubing). Only absolutely clear CSF samples were used for this analysis to avoid overestimation due to serum contamination. Total radioactivity present in the brain, serum, and CSF for each mouse was quantified in a gamma counter, and the results were expressed in the following ratios: brain͞serum (l͞g), brain͞CSF (ml͞g), and CSF͞serum (l͞ml). The formula used to determine these ratios is the same as the brain͞serum ratio formula used for analysis in the capillary depletion experiment. Brain samples were removed and weighed 30 min after the i.v. injection of 131 I-JV-1-42. Cold ammonium acetate solution (4 ml; 10% ammonium acetate with 0.1% BSA in water, pH ϭ 6.87) was added and the brain homogenized with a Polytron homogenizer (Kinematica, Lucerne, Switzerland) on setting 26 for 60 sec. The homogenate was allowed to stand on ice for 2 h and then centrifuged at 5,400 ϫ g for 20 min. The supernatant was removed, lyophilized, and stored until rehydrated 10 min before characterization by HPLC with a Vydac 214 TP54 column. Blood from the carotid artery collected 30 min after injection of 131 I-JV-1-42 in 0.2 ml of LR-BSA was allowed to clot at room temperature for 20-30 min before centrifugation at 5,400 ϫ g for 10 min. The serum was collected, and a quantity of 0.3 ml was added to 4 ml of cold ammonium acetate solution. This mixture was vortexed for 15 sec and allowed to incubate on ice for 2 h. After incubation, the serum was treated with the same procedure used for brain homogenate. The control sample consisted of brain and serum from a mouse that had not been injected. Instead, 131 I-JV-1-42 was added to the brain and serum ex vivo. These control samples were used to correct for any degradation that may have occurred as a result of processing. For comparison, 131 I-JV-1-42 was used as a standard to characterize the elution peak for the labeled peptide analog. Results were expressed as the percent per fraction of total cpm eluted.
Forty 1-ml fractions were collected for each sample. The amount of radioactivity present in each of these fractions was measured in a gamma counter. Fractions 1-5 were excluded from the analysis, because these represented void volume.
Statistical Analysis. Unpaired t tests or one-way ANOVA with the Newman-Keuls multiple comparison test were calculated by using PRISM 4.0 (GraphPad, San Diego). Means are reported with their standard errors. Regression lines were calculated by the least-squares method.
Results
Clearance of 131 I-JV-1-42 from Serum. The early phase of clearance from the serum for 131 I-JV-1-42 followed first-order kinetics. Linear regression analysis showed a significant correlation between log (%Inj͞ml) and time (t), P Ͻ 0.01, for the first 10 min after i.v. injection (Fig. 1A Inset) . Half-life in the serum was calculated from the inverse of the slope of this relation to be Ϸ12.2 min. The initial rapid decline was followed by a steady state that remained unchanged between 30 and 120 min.
Brain Uptake (Influx) of 131 I-JV-1-42 from the Blood. An octanol͞ buffer partition coefficient of 78.31 Ϯ 5.72 indicates that 131 I-JV-1-42 is highly lipid-soluble. Brain uptake for the first 10 min after i.v. injection was rapid (Fig. 1B) , with an influx rate (K i ) of 0.8514 l͞g per min and a V i of 23.87 l͞g (Fig. 1C) . A one-site binding model was used to fit a hyperbola to the values in Fig.  1B . According to this model, the maximal percent of the injected dose taken up by each gram of brain is 0.41%. There were regional differences in brain uptake of 131 I-JV-1-42, with the thalamus taking up a significantly lower percentage of the i.v.-injected dose than both the pons͞medulla and the cerebellum (Fig. 5 , which is published as supporting information on the PNAS web site).
Coinjection of unlabeled peptide did not significantly decrease influx of 131 I-JV-1-42 but instead produced a paradoxical increase in the brain͞serum ratio (P Ͻ 0.05) (Fig. 1D) .
Stability in Blood and Brain. HPLC analysis found no degradation in either brain or serum processing controls or in 10-min experimental samples (Fig. 2 A and C, respectively) . All samples were processed identically before separation by HPLC. For brain and serum samples obtained 30 min after i.v. injection, 69.5% of counts for brain and 68.2% of counts for serum eluted as intact 131 I-JV-1-42. The remaining radioactivity eluted as multiple peaks (Fig. 2B) .
Capillary Depletion. Capillary depletion was performed with and without washout of the vascular space. The results in Fig. 3A show that conducting vascular washout did not significantly reduce the percentage of 131 I-JV-1-42 measured in the paren- Percentage of total radioactivity recovered in the peak was 86.2% and 49.27% in the brain at 10 and 30 min after i.v. injection, respectively. Percentage of total radioactivity recovered in the peak was 90.1% and 42.04% in the serum at 10 and 30 min after i.v. injection, respectively. For the processing controls, the percentage of total radioactivity recovered in the peak was 97% in the brain and 95.48% in the serum.
chyma. This indicates that any
131 I-JV-1-42 detected in the brain was not loosely adhering to the luminal surface of the brain capillaries but was either internalized into the capillaries or had completely crossed the blood-brain barrier to enter brain parenchyma.
Uptake into CSF. Brain, serum, and CSF samples were collected with a mean of 11.5 l of CSF obtained from the posterior fossa for each mouse. Analysis by two-tailed t test revealed that the mean CSF͞serum ratio (45.37 Ϯ 10.58 l͞ml) was not significantly different (P Ͻ 0.05) from the mean brain͞serum ratio (45.37 Ϯ 0.57 l͞g), and the mean CSF͞brain ratio was Ϸ1.0 (1.03 Ϯ 0.25 ml͞g) (Fig. 3B ). This suggests that 131 I-JV-1-42 can equally penetrate the CSF and the brain tissue.
Brain-to-Blood Transport (Efflux) of 131 I-JV-1-42. Labeled antagonist injected into the ventricular system was effluxed from the brain with a half-life of 17.91 min (Fig. 4A) . Coinjection of unlabeled JV-1-42 inhibited 131 I-JV-1-42 efflux, showing that brain-to-blood efflux occurs by a saturable mechanism (Fig. 4B) . Coinjection of cyclosporin A (P-gp substrate) significantly increased the amount of 131 I-JV-1-42 present in the brain; however, coinjection of a different P-gp substrate, verapamil, had an opposite effect (Fig. 6 , which is published as supporting information on the PNAS web site), indicating that efflux may be mediated by P-gp.
Discussion
Brain tumors are the second and fourth leading causes of cancer mortality in children and young adults, respectively (17) . GHRH antagonists have already shown promise as a potential therapy for malignant gliomas; however, their ability to access the CNS after peripheral administration may be impeded at the bloodbrain barrier. CNS access is limited by the blood-brain barrier for chemotherapeutic drugs by two mechanisms: (i) poor penetration of the blood-brain barrier and (ii) brain-to-blood efflux, especially by the P-gp transporter (28) . In the present study, we have examined the kinetics of blood-brain barrier transport for radioactively labeled JV-1-42, a GHRH antagonistic analog, and found it largely overcame both of these difficulties.
The initial volume of distribution into the serum at t ϭ 0 (antilog of the y intercept) was 23.8 l͞g, a value greater than the usual estimate of the vascular space (V i ), which is 8-12 l͞g. However, because the half-life of the peptide in the serum is characteristic of a peptide of this size, any binding to serum proteins may not be of a high affinity. It is also possible that a transporter exists in the peripheral tissues that can rapidly bind and take up the peptide. Previous studies have indicated that tissue uptake of this compound is high (5) . Multiple time regression analysis found the rate of entry of the peptide into the brain (slope of the line, or K i ) is 0.8514 ml͞g per min. This rapid rate of entry corresponds with the high lipophilicity found for 131 I-JV-1-42 (octanol͞buffer partition coefficient of 78.31 Ϯ 5.72). Lipid solubility is a strong predictor of blood-brain barrier permeability because of the high lipid content of cell membranes. A one-site binding hyperbolic model was used to determine the maximal percent of i.v. dose taken up per gram of brain. This value was 0.41%, indicating that brain uptake of 131 I-JV-1-42 is high. By comparison, brain uptake of 131 I-JV-1-42 is 20-fold greater than morphine (29) and 5-fold higher than IL-1␣ (30), two compounds known to cross the blood-brain barrier and exert CNS effects (31) .
We also conducted a study designed to competitively inhibit the influx of the labeled antagonist from blood into the brain (as represented by brain͞serum ratios, an expression of the volume of distribution). Interestingly, results from this study revealed that coinjection of unlabeled peptide paradoxically increased the brain͞ serum ratios for the labeled peptide. One possible explanation for this paradoxical increase is that the labeled peptide is rapidly transported out of the brain. In this case, addition of the unlabeled peptide would saturate the efflux mechanism and thus increase the amount of time the labeled peptide is present in the brain parenchyma. Administration of 131 I-JV-1-42 by i.c.v. injection with and without unlabeled JV-1-42 confirmed saturable efflux of 131 I-JV-1-42.
P-gp is a drug efflux pump present at the abluminal side of the blood-brain barrier. It is associated with resistance to chemotherapy, because it is a ubiquitous transporter that prevents the passage and accumulation of many drugs from the CNS. P-gp also targets endogenous molecules such as the glucocorticoid cortisol (32) and cholesterol (33) , as well as the ␤ amyloid peptide 1-42 (30) . Substrates for P-gp tend to be peptides that are lipophilic or amphipathic; therefore, it is not surprising that 131 I-JV-1-42 efflux is modulated by P-gp. Inhibition of the efflux when cyclosporin A, a P-gp substrate, is coinjected with radioactively labeled JV-1-42 indicates that 131 I-JV-1-42 is likely a P-gp substrate. However, brain efflux of 131 I-JV-1-42 was not inhibited by verapamil, another P-gp substrate. This indicates that the association of 131 I-JV-1-42 with P-gp may be somewhat complicated. Furthermore, this association with P-gp does not appear so robust as to exclude 131 I-JV-1-42 from brain uptake.
Based on previous experience, it is likely these findings in the mouse are applicable to humans, because many aspects of blood-brain barrier permeability, including predictions of penetration based on lipid solubility and the functions of the P-gp efflux system, are conserved across species (34) (35) (36) (37) (38) . Because of their strong structural similarity, other GHRH antagonists are expected to cross the blood-brain barrier as well. Therefore, GHRH antagonistic analogs show great promise for the treatment of cancer, because they bind specifically and with high affinity to splice variants of the GHRH receptor present in many malignant tumors and produce direct antiproliferative effects in these tumor cells (1, 2, (4) (5) (6) . Previous studies have shown that GHRH antagonists can block tumorigenesis and growth of human malignant gliomas xenografted into nude mice and extend the survival of animals with orthotopic tumor implants (8) . The present study extends the range of applications for these analogs, by demonstrating that peripherally administered JV-1-42 can readily penetrate into CNS tissue. Our findings suggest that GHRH antagonists may have potential as a treatment for primary tumors such as malignant glioblastomas and possibly metastases to the brain of tumors that respond to GHRH antagonists, such as breast cancers.
